Peer-reviewed data shows Gilead's drug effective against COVID-19




  • In US
  • 2020-05-22 22:38:46Z
  • By Reuters
FILE PHOTO: A vial of redesivir
FILE PHOTO: A vial of redesivir  

By Deena Beasley

(Reuters) - The U.S. National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences Inc's remdesivir is effective at helping COVID-19 patients recover.

The trial, for which final results are still trickling in, showed that recovery time for patients given remdesivir was shortened by four days, or 31%, compared to placebo patients.

The data detailed in the journal is similar to early data that the NIH released last month from the study, which began in February with 1,063 participants in 10 countries.

Researchers now calculate that after 14 days of follow up, 7% of patients given remdesivir will have died, compared with 12% in the placebo group, but they said the difference in the death rate was not significant.

"Our findings highlight the need to identify COVID-19 cases and start antiviral treatment before the pulmonary disease progresses to require mechanical ventilation," the researchers wrote.

They noted that "given high mortality despite the use of remdesivir," it is likely that the antiviral drug would be more effective in combination with other treatments for COVID-19, the respiratory illness caused by the novel coronavirus.

The Food and Drug Administration authorized emergency use of remdesivir on May 1, and Gilead has been supplying the drug to hospitals as part of a pledge to donate 1.5 million vials - or enough for at least 140,000 patients.


(Reporting by Manojna Maddipatla in Bengaluru; Editing by Aditya Soni and Aurora Ellis)

COMMENTS

More Related News

Taiwan approves Gilead
Taiwan approves Gilead's remdesivir to treat COVID-19
  • US
  • 2020-05-30 06:29:01Z

Taiwan's government said on Saturday it had approved Gilead Sciences' potential COVID-19 treatment, remdesivir, to treat the illness caused by the novel coronavirus. Governments are racing to bolster supplies of remdesivir, which U.S. regulators this month approved for emergency use. California-based Gilead has said it will donate 1.5 million doses of remdesivir, enough to treat at least 140,000 patients, to combat the global pandemic.

Gilead Continues to Build Cancer Franchise
Gilead Continues to Build Cancer Franchise

Partnership with Arcus Biosciences follows acquisitions of Kite Pharmaceuticals and Forty Seven Continue reading...

EU regulator promises speedy review of potential COVID-19 drug remdesivir
EU regulator promises speedy review of potential COVID-19 drug remdesivir
  • US
  • 2020-05-29 11:38:54Z

The European Medicines Agency (EMA) said on Friday its human medicines committee's (CHMP) timeline to assess the drug would be "reduced to the absolute minimum,". The announcement comes two weeks after the EMA head told the European Parliament it may give an initial green light for sale of remdesivir as a COVID-19 treatment, fast-tracking the drug to market amid tight global competition for resources. The United States, the world's biggest pharmaceutical market, earlier this month granted emergency use authorization for remdesivir in COVID-19, clearing the way for broader use of the drug, but is yet to approve it.

Pakistan drug firm to import potential COVID-19 treatment from Bangladesh
Pakistan drug firm to import potential COVID-19 treatment from Bangladesh
  • US
  • 2020-05-29 11:15:26Z

A pharmaceutical company in Pakistan plans to import the antiviral drug remdesivir, which has shown promise in treating coronavirus patients, from neighbouring Bangladesh, it said in a stock exchange filing on Friday. The announcement by Searle Company Limited came a day after 56 virus deaths recorded by the south Asian nation, its highest toll in a single day. The firm said it had entered into an exclusive licensing and marketing agreement with Bangladesh's Beximco Pharmaceuticals, the first company in the world to introduce the generic variant of the drug.

South Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge
South Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge

South Korean health authorities said on Friday they would request imports of Gilead Sciences Inc's anti-viral drug remdesivir to treat COVID-19, as new outbreaks of the disease flare as social distancing restrictions are eased. The Ministry of Food and Drug Safety must approve the import but a government panel concluded remdesivir showed positive results, Korea Centers for Disease Control and Prevention (KCDC) Director Jeong Eun-kyeong said. Foster City, California-based Gilead has said the drug has improved outcomes for people suffering from the respiratory disease caused by the novel coronavirus and has provided data suggesting it works better when given in the early stages of infection.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US